With such substantial overlap between BRAF mutations and PD-L1 expression, our combined findings would support consideration of a clinical trial using BRAF/MEK inhibitors in combination with immune checkpoint inhibitors in craniopharyngioma patients with refractory or residual disease and in the neoadjuvant setting prior to radiation therapy. Here, CD274 is linked to craniopharyngioma.